BloodHumansBiomarkersTumorBridged Bicyclo CompoundsHeterocyclic
Measurable residual disease intervention in AML: a new therapeutic horizon.
Andrew H Wei, Harry J Iland, Courtney D DiNardo, John Reynolds
Published: 202610.1182/blood.2025029010
Abstract
ABSTRACT: Acute myeloid leukemia (AML) is a polyclonal malignancy marked by high relapse rates despite initial morphologic remission. Although measurable residual disease (MRD) is an established prognostic tool, increasing evidence supports a role fo…
Preview only. Read the full abstract at the source